Nova Biomedical Awarded Multi-Year Glucose Monitoring System Agreement With Premier, Inc.
Posted February 12th, 2012.
WALTHAM, Mass. January 2010 – Nova Biomedical announced it has been awarded a new multi-year glucose monitoring system agreement with Premier Purchasing Partners, the group purchasing unit of Premier, Inc. This new agreement provides Premier members access to contracts for Nova’s lab-accurate and interference-free StatStrip® Glucose technology for monitoring glucose levels in hospital patients.
The agreement is effective March 1, 2010 and runs through February 28, 2013. Products on the agreement include Nova’s StatStrip Glucose Monitoring System meters and advanced technology test strips, docking stations and wireless totes.
“We are pleased Premier has selected our technically advanced StatStrip® Glucose technology to help them achieve their commitment to superior patient care,” said Richard Schneider, Vice President of National Accounts for Nova. “This agreement will benefit both organizations and will now allow Premier members to provide lab-accurate glucose results at the bedside. We look forward to working with Premier and its members to implement StatStrip technology at their hospitals.”
StatStrip Glucose Monitoring System uses a novel glucose test strip technology that measures and eliminates hematocrit and other common interferences such as maltose, galactose, xylose, acetaminophen, ascorbic acid and oxygen, and eliminates erroneous glucose results caused by these interfering substances. StatStrip lab-like accuracy and freedom from interference has been validated in more than 32 published clinical studies worldwide, in a broad variety of critical care settings including ICU, Dialysis, NICU, OR, ED, and Tertiary Care. This remarkable rate of StatStrip publications by some of the world’s leading hospitals, is testimony to the importance of this technology breakthrough for bedside glucose testing.
About Premier Inc., 2006 Malcolm Baldrige National Quality Award recipient
The Premier healthcare alliance is more than 2,300 U.S. hospitals and 64,000-plus other healthcare sites working together to improve healthcare quality and affordability. Owned by not-for-profit hospitals, Premier maintains the nation’s most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier works with the Centers for Medicare & Medicaid Services and the United Kingdom’s National Health Service North West to improve hospital performance.
About Nova Biomedical
Nova Biomedical, incorporated in 1976, is a world leader in the development and manufacturing of state-of-the-art whole blood chemistry analyzers. The Nova product line ranges from small single-test meters for glucose self-testing and hospital-based point of care testing to full critical-care whole blood analyzers designed for rapid measurement of over 20 analytes. Nova products are used by small, medium, and large hospitals, as well as integrated health networks, to improve patient outcomes and reduce the cost of care.
*******
For further information, please contact:
Rick Rollins
Nova Biomedical,
200 Prospect Street,
Waltham, MA 02454, USA
Tel: 781-647-3700 x579 / Fax: 781-894-5915 / Email: rrollins@novabio.com